Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) – Pipeline Review, H2 2016’, provides in depth analysis on Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted pipeline therapeutics.

The report provides comprehensive information on the Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC)

The report reviews Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics and enlists all their major and minor projects

The report assesses Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

AbbVie Inc

Advinus Therapeutics Ltd

Arrien Pharmaceuticals, LLC

Aurigene Discovery Technologies Limited

Beijing Hanmi Pharmaceutical Co., Ltd.

Biogen Inc

Brickell Biotech, Inc.

Bristol-Myers Squibb Company

Celgene Corporation

Eli Lilly and Company

Genentech, Inc.

Genfit SA

GlaxoSmithKline Plc

Japan Tobacco Inc.

Lead Pharma Holding B.V.

Nuevolution AB

Pfizer Inc.

Phenex Pharmaceuticals AG

Reata Pharmaceuticals, Inc.

Takeda Pharmaceutical Company Limited

Teijin Pharma Limited

Visionary Pharmaceuticals, Inc.

Vitae Pharmaceuticals, Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) Overview 10

Therapeutics Development 11

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Products under Development by Stage of Development 11

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Products under Development by Therapy Area 12

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Products under Development by Indication 13

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Pipeline Products Glance 15

Late Stage Products 15

Early Stage Products 16

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Products under Development by Companies 17

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Products under Development by Universities/Institutes 22

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Therapeutics Assessment 24

Assessment by Monotherapy/Combination Products 24

Assessment by Mechanism of Action 25

Assessment by Route of Administration 27

Assessment by Molecule Type 29

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Companies Involved in Therapeutics Development 30

AbbVie Inc 30

Advinus Therapeutics Ltd 31

Arrien Pharmaceuticals, LLC 32

Aurigene Discovery Technologies Limited 33

Beijing Hanmi Pharmaceutical Co., Ltd. 34

Biogen Inc 35

Brickell Biotech, Inc. 36

Bristol-Myers Squibb Company 37

Celgene Corporation 38

Eli Lilly and Company 39

Genentech, Inc. 40

Genfit SA 41

GlaxoSmithKline Plc 42

Japan Tobacco Inc. 43

Lead Pharma Holding B.V. 44

Nuevolution AB 45

Pfizer Inc. 46

Phenex Pharmaceuticals AG 47

Reata Pharmaceuticals, Inc. 48

Takeda Pharmaceutical Company Limited 49

Teijin Pharma Limited 50

Visionary Pharmaceuticals, Inc. 51

Vitae Pharmaceuticals, Inc. 52

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Drug Profiles 53

ABBV-553 - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

ARN-6039 - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

BBI-6000 - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

Drug to Antagonize ROR-Gamma for Psoriasis, Psoriatic Arthritis and Axial Spondyloarthritis - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

GSK-2981278 - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

INV-17 - Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

JTE-451 - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

Small Molecule to Agonize ROR-Gamma for Inflammation, Respiratory and Oncology - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

Small Molecule to Antagonize RAR-Related Orphan Receptor Gamma for Psoriasis - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

Small Molecule to Antagonize ROR-Gamma for Multiple Sclerosis - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

Small Molecule to Target ROR Gamma for Autoimmune Disorders - Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

Small Molecules to Agonize RAR-Related Orphan Receptor Gamma for Inflammatory Bowel Disease - Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

Small Molecules to Agonize ROR gamma for Breast Cancer - Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

Small Molecules to Agonize ROR-Gamma for Autoimmune Disease - Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

Small Molecules to Agonize ROR-Gamma for Oncology - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

Small Molecules to Antagonize ROR-Gamma for Autoimmune Disorders - Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

Small Molecules to Antagonize ROR-Gamma T for Rheumatoid Arthritis and Psoriasis - Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

Small Molecules to Antagonize RORc for Autoimmune Diseases and Inflammation - Drug Profile 72

Product Description 72

Mechanism Of Action 72

R&D Progress 72

Small Molecules to Antagonize RORC for Immunology, Multiple Sclerosis and Non-Alcoholic Steatohepatitis - Drug Profile 73

Product Description 73

Mechanism Of Action 73

R&D Progress 73

Small Molecules to Antagonize RORC for Immunology, Multiple Sclerosis, Non-Alcoholic Steatohepatitis - Drug Profile 74

Product Description 74

Mechanism Of Action 74

R&D Progress 74

Small Molecules to Inhibit ROR gamma-t for Autoimmune Diseases - Drug Profile 75

Product Description 75

Mechanism Of Action 75

R&D Progress 75

Small Molecules to Inhibit ROR gamma-t for Multiple Sclerosis and Rheumatoid Arthritis - Drug Profile 76

Product Description 76

Mechanism Of Action 76

R&D Progress 76

Small Molecules to Inhibit ROR-Gamma for Inflammation - Drug Profile 77

Product Description 77

Mechanism Of Action 77

R&D Progress 77

Small Molecules to Inhibit ROR-Gamma T for Autoimmune Disorders and Inflammation - Drug Profile 78

Product Description 78

Mechanism Of Action 78

R&D Progress 78

Small Molecules to Target ROR gamma for Autoimmune Diseases - Drug Profile 79

Product Description 79

Mechanism Of Action 79

R&D Progress 79

SR-1001 - Drug Profile 80

Product Description 80

Mechanism Of Action 80

R&D Progress 80

SR-2211 - Drug Profile 81

Product Description 81

Mechanism Of Action 81

R&D Progress 81

TAK-828 - Drug Profile 82

Product Description 82

Mechanism Of Action 82

R&D Progress 82

TGFTX-1 - Drug Profile 83

Product Description 83

Mechanism Of Action 83

R&D Progress 83

TMP-778 - Drug Profile 84

Product Description 84

Mechanism Of Action 84

R&D Progress 84

VPR-66 - Drug Profile 85

Product Description 85

Mechanism Of Action 85

R&D Progress 85

VTP-43742 - Drug Profile 86

Product Description 86

Mechanism Of Action 86

R&D Progress 86

VTP-45489 - Drug Profile 88

Product Description 88

Mechanism Of Action 88

R&D Progress 88

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Dormant Projects 89

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Discontinued Products 90

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Featured News & Press Releases 91

Jun 06, 2016: Vitae Pharmaceuticals Announces Appointment of Carole Sable, M.D., as Chief Medical Officer 91

Jun 03, 2016: Arrien Pharmaceuticals Initiated Phase I Clinical Trials of ARN-6039 as a New Agent for Treatment of Multiple Sclerosis 91

May 09, 2016: Arrien Pharmaceuticals to Initiate the Phase I Clinical trials of Autoimmune Drug 92

Apr 29, 2016: Arrien Pharmaceuticals Announces FDA Accepts IND Application For ARN-6039 92

Mar 16, 2016: Vitae Pharmaceuticals Achieves Proof-of-Concept with First-in-Class RORyt Inhibitor in Moderate to Severe Psoriasis 93

Nov 18, 2015: Vitae Pharmaceuticals Announces Positive Top-Line Results From a Phase 1 Multiple Ascending Dose Trial of VTP-43742 93

Nov 03, 2015: Lycera Announces Progress in Immuno-Oncology Program to be Presented at Society for Immunotherapy of Cancer (SITC) 2015 Annual Meeting 94

Nov 02, 2015: Lead Pharma Achieves first Milestone for Developmen t of Autoimmune Diseases Treatments in Research Collabor ation with Sanofi 95

Sep 29, 2015: Vitae Pharmaceuticals Initiates Second Part of a Phase 1 Multiple Ascending Dose Study of VTP-43742 in Psoriatic Patients 96

Sep 08, 2015: Vitae Pharmaceuticals Announces Positive Top-Line Results From Initial Phase 1 Study of First-in-Class RORyt Inhibitor VTP-43742 in Autoimmune Disorders 96

Aug 10, 2015: Vitae Pharmaceuticals Announces Initiation of a Phase 1 Multiple Ascending Dose Study of VTP-43742 in Autoimmune Disorders 97

Aug 05, 2015: Aurigene to Present its RORg Inverse Agonist Program at World Congress on Inflammation, 2015 97

Jun 29, 2015: Vitae Pharmaceuticals Announces Initiation of a Phase 1 Single Ascending Dose Study of VTP-43742 in Autoimmune Disorders 98

Apr 16, 2015: Vitae Pharmaceuticals to Present at Keystone Symposia on Mechanisms of Pro-Inflammatory Diseases 98

Mar 17, 2015: New Compound Prevents Type 1 Diabetes in Animal Models–Before It Begins 99

Appendix 100

Methodology 100

Coverage 100

Secondary Research 100

Primary Research 100

Expert Panel Validation 100

Contact Us 100

Disclaimer 101

List of Tables

List of Tables

Number of Products under Development for, H2 2016 11

Number of Products under Development by Therapy Area, H2 2016 12

Number of Products under Development by Indication, H2 2016 14

Comparative Analysis by Late Stage Development, H2 2016 15

Comparative Analysis by Early Stage Products, H2 2016 16

Number of Products under Development by Companies, H2 2016 17

Products under Development by Companies, H2 2016 18

Products under Development by Companies, H2 2016 (Contd..1) 19

Products under Development by Companies, H2 2016 (Contd..2) 20

Products under Development by Companies, H2 2016 (Contd..3) 21

Number of Products under Investigation by Universities/Institutes, H2 2016 22

Products under Investigation by Universities/Institutes, H2 2016 23

Assessment by Monotherapy/Combination Products, H2 2016 24

Number of Products by Stage and Mechanism of Action, H2 2016 26

Number of Products by Stage and Route of Administration, H2 2016 28

Number of Products by Stage and Molecule Type, H2 2016 29

Pipeline by AbbVie Inc, H2 2016 30

Pipeline by Advinus Therapeutics Ltd, H2 2016 31

Pipeline by Arrien Pharmaceuticals, LLC, H2 2016 32

Pipeline by Aurigene Discovery Technologies Limited, H2 2016 33

Pipeline by Beijing Hanmi Pharmaceutical Co., Ltd., H2 2016 34

Pipeline by Biogen Inc, H2 2016 35

Pipeline by Brickell Biotech, Inc., H2 2016 36

Pipeline by Bristol-Myers Squibb Company, H2 2016 37

Pipeline by Celgene Corporation, H2 2016 38

Pipeline by Eli Lilly and Company, H2 2016 39

Pipeline by Genentech, Inc., H2 2016 40

Pipeline by Genfit SA, H2 2016 41

Pipeline by GlaxoSmithKline Plc, H2 2016 42

Pipeline by Japan Tobacco Inc., H2 2016 43

Pipeline by Lead Pharma Holding B.V., H2 2016 44

Pipeline by Nuevolution AB, H2 2016 45

Pipeline by Pfizer Inc., H2 2016 46

Pipeline by Phenex Pharmaceuticals AG, H2 2016 47

Pipeline by Reata Pharmaceuticals, Inc., H2 2016 48

Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 49

Pipeline by Teijin Pharma Limited, H2 2016 50

Pipeline by Visionary Pharmaceuticals, Inc., H2 2016 51

Pipeline by Vitae Pharmaceuticals, Inc., H2 2016 52

Dormant Projects, H2 2016 89

Discontinued Products, H2 2016 90

List of Figures

List of Figures

Number of Products under Development for, H2 2016 11

Number of Products under Development by Therapy Area, H2 2016 12

Number of Products under Development by Top 10 Indication, H2 2016 13

Comparative Analysis by Early Stage Products, H2 2016 16

Assessment by Monotherapy/Combination Products, H2 2016 24

Number of Products by Mechanism of Actions, H2 2016 25

Number of Products by Stage and Mechanism of Actions, H2 2016 25

Number of Products by Routes of Administration, H2 2016 27

Number of Products by Stage and Routes of Administration, H2 2016 27

Number of Products by Stage and Molecule Type, H2 2016 29

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports